Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RIP140 small interfering RNA
- Development stage
- Preclinical
- Lead developer
- LadRx
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, Pulmonary, Other (experimental In Vitro Transfection/electroporation)
01
Overview
RIP140 small interfering RNA is an RNA interference (RNAi)-based therapeutic candidate developed by CytRx R&D Company for the treatment of obesity and type 2 diabetes. The drug utilizes small interfering RNA (siRNA) to target and silence the expression of Receptor-interacting protein 140 (RIP140), also known as Nuclear receptor-interacting protein 1 (NRIP1). RIP140 is a transcriptional corepressor that normally inhibits metabolic pathways; its depletion leads to the upregulation of genes involved in glucose uptake, glycolysis, fatty acid oxidation, and mitochondrial biogenesis. In preclinical models, this mechanism has demonstrated the ability to increase metabolic rate and provide resistance to diet-induced obesity.
- Other names
- RIP140 siRNARIP-140 siRNARIP 140 siRNANRIP1 siRNANRIP-1 siRNANRIP 1 siRNANRIP1 small interfering RNANRIP-1 small interfering RNANRIP 1 small interfering RNA
02
Targets
NRIP1 (Nuclear receptor-interacting protein 1)
Beyond the preview
Go deeper on RIP140 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RIP140 small interfering RNA.